These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32466836)

  • 21. Results of the COMPASS trial analysed using win ratio compared with conventional analytic approaches.
    Eikelboom JW; Yi Q; McIntyre WF; Bosch J; Whitlock R; Connolly SJ; Scheier TC; Muehlhofer E; Pap ÁF; Pocock SJ; Bangdiwala SI
    Can J Cardiol; 2024 Jul; ():. PubMed ID: 39002945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long-term studies.
    Messori A; Bartoli L; Trippoli S
    ESC Heart Fail; 2021 Jun; 8(3):2345-2348. PubMed ID: 33733623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The win ratio method in heart failure trials: lessons learnt from EMPULSE.
    Pocock SJ; Ferreira JP; Collier TJ; Angermann CE; Biegus J; Collins SP; Kosiborod M; Nassif ME; Ponikowski P; Psotka MA; Teerlink JR; Tromp J; Gregson J; Blatchford JP; Zeller C; Voors AA
    Eur J Heart Fail; 2023 May; 25(5):632-641. PubMed ID: 37038330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease: A Novel Analysis of the VITAL Trial Using Win Ratio and Hierarchical Composite Outcomes.
    Ogata S; Manson JE; Kang JH; Buring JE; Lee IM; Nishimura K; Sakata Y; Danik JS; D'Agostino D; Mora S; Albert CM; Cook NR
    Nutrients; 2023 Sep; 15(19):. PubMed ID: 37836519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical power considerations in the use of win ratio in cardiovascular outcome trials.
    Wang B; Zhou D; Zhang J; Kim Y; Chen LW; Dunnmon P; Bai S; Liu Q; Ishida E
    Contemp Clin Trials; 2023 Jan; 124():107040. PubMed ID: 36470557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis.
    Wu H; Hou Y; Chen Z
    J Eval Clin Pract; 2023 Feb; 29(1):211-217. PubMed ID: 35945813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of the Win Ratio Analysis in Critical Care Trials.
    Monzo L; Levy B; Duarte K; Baudry G; Combes A; Ouattara A; Delmas C; Kimmoun A; Girerd N
    Am J Respir Crit Care Med; 2024 Apr; 209(7):798-804. PubMed ID: 38285595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Win Statistics in Observational Cancer Research: Integrating Clinical and Quality-of-Life Outcomes.
    Chiaruttini MV; Lorenzoni G; Spolverato G; Gregori D
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892983
    [No Abstract]   [Full Text] [Related]  

  • 29. On recurrent-event win ratio.
    Mao L; Kim K; Li Y
    Stat Methods Med Res; 2022 Jun; 31(6):1120-1134. PubMed ID: 35345957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Event-specific win ratios and testing with terminal and non-terminal events.
    Yang S; Troendle J
    Clin Trials; 2021 Apr; 18(2):180-187. PubMed ID: 33231108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of semiparametric approaches to evaluate composite endpoints in heart failure trials.
    Toenges G; Mütze T; Jahn-Eimermacher A
    Stat Med; 2021 Nov; 40(26):5702-5724. PubMed ID: 34327735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The win ratio approach for composite endpoints: practical guidance based on previous experience.
    Redfors B; Gregson J; Crowley A; McAndrew T; Ben-Yehuda O; Stone GW; Pocock SJ
    Eur Heart J; 2020 Dec; 41(46):4391-4399. PubMed ID: 32901285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A class of proportional win-fractions regression models for composite outcomes.
    Mao L; Wang T
    Biometrics; 2021 Dec; 77(4):1265-1275. PubMed ID: 32974905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power.
    Sampson UK; Metcalfe C; Pfeffer MA; Solomon SD; Zou KH
    J Clin Epidemiol; 2010 Oct; 63(10):1156-8. PubMed ID: 20558037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of the win odds in the design of non-inferiority clinical trials.
    Peng L
    J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.
    Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Yasui Y; Johnson JA
    Open Med; 2010; 4(1):e40-8. PubMed ID: 21686293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of win time for ordered composite endpoints in clinical trials.
    Troendle JF; Leifer ES; Yang S; Jeffries N; Kim DY; Joo J; O'Connor CM
    Stat Med; 2024 May; 43(10):1920-1932. PubMed ID: 38417455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions.
    Ajufo E; Nayak A; Mehra MR
    JACC Basic Transl Sci; 2023 Jun; 8(6):720-727. PubMed ID: 37426527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its components.
    Liao R; Chakladar S; Gamalo M
    Pharm Stat; 2022 Nov; 21(6):1342-1356. PubMed ID: 35766113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical models for composite endpoints of death and non-fatal events: a review.
    Mao L; Kim K
    Stat Biopharm Res; 2021; 13(3):260-269. PubMed ID: 34540133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.